Biotech stocks will likely remain pressured from Brexit volatility, despite stocks rising on Tuesday. That makes investing in these already highly volatile stocks even trickier, but there are opportunities. 

Cantor Fitzgerald analysts Mara Goldstein and Monica Gorman suggest that investors stick to investing in biotech companies that have "long cash runways" and "low to moderate clinical risk" as the "better defensive positioning in the group," according to a note Tuesday.

"Biotechnology companies that raise capital can oftentimes be penalized for accessing the markets, though it is this activity that provides a cushion, in our view, in leaner times," they wrote. "We think that companies with significant cash runways have less financing risk, and are more likely to maintain R&D productivity."

The analysts highlighted four biotech stocks -- Radius Health (RDUS) - Get Report , Applied Genetics Technologies (AGTC) - Get Report , Relypsa (RLYP) and OncoMed Pharmaceuticals (OMED) - Get Report -- that have "strong cash runways" and trade at modest multiples of cash.

Goldstein and Gorman also highlighted biotech companies with minimal clinical risk as being relatively less volatile.

Companies with "fewer binary events or a diverse portfolio to mitigate the potential loss of a clinical candidate," include Radius Health, Applied Genetics Technologies, Relypsa, Seattle Genetics (SGEN) - Get Report , Array (ARRY) - Get Report , and OncoMed. They note that the "counterbalance to this is liquidity, with some companies, such as Seattle Genetics, Radius Health and Relypsa, having greater daily trading volumes."

Radius Health, Applied Genetics, Relypsa, OncoMed and Seattle Genetics are the analysts' top stocks in the sector to withstand Brexit-induced volatility.

Here is more information on each of the five stocks.